

2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways

PUBLICATIONS | LESS THAN 1 MIN READ

April 17, 2018


By: Ross Blau

Westlaw Journal

Ross Blau co-authored, “2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways” with Jonathan Harris and Drew Hillier which was published by *Westlaw Journal Medical Devices*, *Westlaw Journal Products Liability*, *Westlaw Journal Health Law*, *Westlaw Journal Pharmaceutical* and *Westlaw Journal Intellectual Property*. The article discusses nuanced shifts in Federal Circuit opinions and the lessons that can be gleaned from them.

Click [here](#) to access the article.

Related People



Ross E. Blau

Related Services

Intellectual Property

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
SPONSORSHIP ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST

- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
- AXINN VIEWPOINTS LITIGATION & TRIALS**

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved